关于“阳光电源”的报告
-
-
-
-
艾媒咨询|2021-2022年中国医美器械产业运行及投资决策分析报告
本报告研究涉及企业/品牌/案例：科医人，复星医药，奇致激光，半岛医疗
伴随着医美市场规模的持续扩大，中国医美器械行业发展前景可期。数据显示，预计2021年中国医美器械市场规模将超过500亿元，同比增长27.8%。从细分赛道来看，近年来，微创和无创已逐渐成为医疗美容的趋势，这就推动了以激光、超声波等能量源为代表的光电类医美器械的发展。从市场格局来看，中国正规医美机构设备的市场份额80%是进口品牌，且中高端市场被飞顿、塞诺龙等海外龙头企业占领。为了改变这一局面，国家及地方先后出台政策鼓励本土医美器械品牌的发展，同时，国有品牌也通过加大自主研发投入和投资并购来扩大市场份额，未来随着下游扩张、需求渗透、技术更新等因素有望加速进口替代。
With the continuous expansion of the medical beauty market, the development prospect of the medical beauty equipment industry in China is promising. According to the data, it is estimated that in 2021, the market size of medical devices in China will exceed 50 billion yuan, with a year-on-year growth of 27.8%. From the perspective of subdivision, in recent years, minimally invasive and non-invasive have gradually become the trend of medical beauty, which promotes the development of photoelectric medical beauty devices represented by laser, ultrasonic and other energy sources. From the perspective of market structure, 80% of the market share of China's regular medical and beauty institutions' equipment is imported brands, and the medium and high-end market is occupied by overseas leading enterprises such as feton and sinolon. In order to change this situation, the state and local governments have successively issued policies to encourage the development of local medical and beauty equipment brands. At the same time, the state-owned brands also expand their market share by increasing independent R & D investment and investment in M & A. in the future, with the downstream expansion, demand penetration, technology update and other factors, it is expected to accelerate the import substitution. -
艾媒咨询|2020上半年中国共享充电宝行业发展专题研究报告
本报告研究涉及企业/品牌/案例：小电科技、街电科技、美团充电。
在质疑声中走过发展爆发和沉淀阶段的中国共享充电宝行业，在2019年进入了规范发展时期，即使2020年受到“新冠疫情”影响，行业发展整体向好的趋势没有改变。iiMedia Research（艾媒咨询）数据显示，2020年用户规模预计达到2.29亿人。但短期内疫情对行业的冲击仍然不容忽视，八成受访共享充电宝用户表示产品使用习惯受到疫情影响发生了变化。具体表现为使用次数降低、时间缩短，其中对于出行场景和大机柜共享充电宝的使用影响尤为严重。行业竞争方面同样迎来变数，美团在年初启动共享充电宝业务，凭借其积累的线下商家资源和自身产品体验优势，避开了新入局企业进入门槛过高等问题，对行业头部企业形成冲击。
China Shared Power Bank Industry, which has gone through the development stages of outbreak and precipitation despite queries, has entered the period of standardized development in 2019. Even though it is affected by the COVID-19 in 2020, the overall development trend of the industry will not change. As the data of iiMedia Research showed, the user scale of China Shared Power Bank industry is expected to reach 229 million in 2020. However, in the short term, the impact of COVID-19 on the industry can’t be ignored. 80% of the interviewees reflected that their use habits of shared power bank has changed due to the impact of COVID-19. Specifically, the usage frequency are reduced and the time is shortened, especially for the usage of shared power bank in travel scenario and the ones in large cabinet. The industry competition also ushered in variables. Meituan launched the shared power bank business at the beginning of the year. Relying on its advantages of accumulated offline business resources and better product experiences, Meituan avoided the problem of high entry threshold for new competitors, and having an impact on the leading enterprises in the industry. -
艾媒报告|2020年中国TWS无线耳机专题研究报告
iiMedia Research（艾媒咨询）数据显示，预计到2020年，中国TWS无线耳机销量将超三千万件，虽然受疫情影响，2020年市场销售规模增长将全面降速，但基于整体市场初步的发展阶段，销售量仍将维持正向增长，市场前景普遍受看好。同时，包括智能终端无孔化趋势、蓝牙技术、芯片技术的不断提升，也将进一步加快TWS无线耳机的产品普及。另外，根据iiMedia Research（艾媒咨询）数据显示，41.8%的受访受访者能够接受500元以下的TWS无线耳机价格， TWS无线耳机中低端市场仍有较大用户群可挖掘。
According to the data of iiMedia Research, it is estimated that by 2020, the sales volume of TWS wireless earphones in China will exceed 30 million. Although affected by the epidemic situation, the growth of the market sales scale in 2020 will be slowed down in an all-round way, based on the preliminary development stage of the overall market, the sales volume will maintain a positive growth and the market prospect will be generally optimistic. At the same time, it will further accelerate the popularization of TWS wireless earphone products, including the trend of smart terminal non porous, the continuous improvement of Bluetooth technology and chip technology. In addition, according to the data of iiMedia Research, 41.8% of the respondents can accept the price of TWS wireless earphone below 500 yuan. There is still a large user group in the middle and low-end market of TWS wireless earphone. -
艾媒报告|2019年12月-2020年1月中国医疗器械行业运行及上市公司双月度报告
本报告研究涉及企业/品牌包括:Mavidon,Titan Medical,Aspire Capital Fund,CentriMag,汇桥资本集团,联影医疗技术集团,医达极星,大博医疗,安捷伦,润扬医疗器械,迈瑞医疗,乐普医疗,威高医用,华大基因,安图生物,健帆生物,鱼跃医疗,京东方科技,美亚光电,东软集团,祥生医疗,硕世生物,佰仁医疗,爱博诺德,伟思医疗,安必平,林华医疗,拱东医疗,天智航,三友医疗,赛科希德等。
截至 2020 年 1 月 31 日 24:00，国家卫生健康委员会公布全国确诊病例 11791 例，重症病例 1795 例。短期来看，预计疫情将继续持续一段时间。肺炎疫情期间，病毒检测带动试剂盒需求增加；病毒治疗带动医用设备及医用耗材需求增加。部分医疗器械企业有望构成业绩增厚。
As of 24:00 on January 31, 2020, the National Health Commission announced 11791 confirmed cases and 1795 severe cases. In the short term, the outbreak is expected to continue for some time. During the pneumonia epidemic, virus detection drives demand for kits; virus treatment drives demand for medical equipment and supplies. Some medical device companies are expected to increase their performance. -
艾媒报告 |2019全球及中国口腔护理行业状况与发展趋势大数据分析报告
本报告研究涉及企业/品牌/案例：Straumann,invisalign,隐适美，美亚光电，BEGO，MISI，DENT，JUST，博恩登特，卡瓦集团，NewTom , Dentply Sirona , PLAMENCE , UEG MEDICAL, 泰康拜博口腔，北京大学口腔医院，拜瑞口腔，佳兆业健康集团，国瓷材料，土卓曼集团，牙医管家，茄子，武汉大学口腔医院，通策医疗，可恩口腔，牙博士口腔，阿里健康，一牙网，爱牙，牙医帮
2019年，中国5岁儿童及12岁儿童的龋齿患病率分别为70.9%和34.5%，成年人和老年人群体的牙周问题严重，中国居民口腔健康亟待改善。在国家政策的支持下，2010-2017年间，中国人均卫生费用涨至3738.8元，中国专科医院数量不断上升，口腔医院就诊人数增长到3587.6万人。从中国口腔市场的上下游产业链看，上游端器械市场以Straumann为代表的种植牙企业、典型正畸品牌隐适美以及CBCT巨头亚美广电均实现营收增长，分别于增长了20.7%、37.8%和36.1%；下游端，民营口腔机构达到6.5万个，占据14.2%的市场份额。艾媒咨询分析师认为，民营口腔医疗机构将成为未来中国口腔护理行业投资大市场，并且，“互联网+”和“商业保险+”的模式将逐渐普及。
In 2019, the prevalence of dental caries in Chinese 5-year-old children and 12-year-old children was 70.9% and 34.5%, respectively. Adults had severe periodontal problems, the bleeding rate of gingiva was 87.4%, and the detection rate of calculus was as high as 96.7%. Health needs to be improved. The National Health and Health Committee has established a clear indicator of oral health in 2020-2025. It is expected that the child prevalence rate will be controlled below 30.0%, and the number of remaining teeth in the elderly will reach 24. In 2010-2017, the per capita health expenditure in China rose to 3738.8 yuan. The number of specialized hospitals in China continued to rise. The stomatological hospitals had a large room for development. The number of patients in stomatological hospitals increased to 35.876 million, while the market for Chinese oral stocks was only 103.50 billion yuan. There is an incremental market with great potential. China's oral care upstream device market is expected to reach US$18.30 billion in 2022. The dental implant companies represented by Straumann, the typical orthodontic brand Invisialign and the CBCT giant Meyer all have achieved revenue growth, up 20.7% respectively. 37.8% and 36.1%. At the downstream end, the number of private dental institutions reached 65,000, accounting for 14.2% of the market. It represents the company's Taikang Baibo oral, joint commercial insurance and Internet platform, achieving one-stop service of “insurance + oral care”, as well as online and offline, the omni-channel service model, with revenue growth in 2017, reached 1.43 billion yuan. -
艾媒报告 |2019年中国柔性显示产业研究与商业投资决策分析报告
本报告研究涉及企业/品牌包括:三星、iPhone、华为、小米、OPPO、京东方、深天马A、TCL集团、微信诺、华星光电、信利国际、和辉光电、柔宇科技、中能源、湖南群显、联得装备、同兴达、志云股份、国风塑业、新纶科技、时代新材、鼎龙股份、激智科技、晶华新材、万润股份、强力新材、东旭光电、莱宝高科、长信科技、ST康得新、中颖电子、士兰微、凯盛科技、康达新材、西部材料、传艺科技、金明精机、光莆股份、样子想你才、神宇股份、海顺新材、茂硕电源
政策支持和技术进步共同推动中国柔性显示产业快速发展。iiMedia Research(艾媒咨询)监测发现，2018年中国柔性显示游产业链各个环节相关企业营收均超亿元，相关上市公司中京东方A(000725.SZ)的网络关注度最高，隆华科技(300263.SZ)的网络口碑最好。但由于技术门槛高等相关因素影响，中国柔性显示产业上游发展基础薄弱，产业存在发展不成熟、技术欠缺和市场份额不足等问题。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
- 1
- 2
- 3
- 4
- 5
